Valuation: Nuvalent, Inc.

Capitalization 5.54B 5.27B 4.97B 4.39B 7.85B 480B 8.71B 59.2B 21.93B 201B 20.76B 20.34B 842B P/E ratio 2024 *
-19.8x
P/E ratio 2025 * -17.2x
Enterprise value 4.55B 4.33B 4.09B 3.61B 6.45B 394B 7.16B 48.68B 18.03B 165B 17.07B 16.72B 692B EV / Sales 2024 *
-
EV / Sales 2025 * 705x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.73%
1 week-9.05%
Current month-9.18%
1 month+0.63%
3 months-10.30%
6 months+8.37%
Current year-0.45%
More quotes
1 week
77.84
Extreme 77.84
87.66
1 month
74.34
Extreme 74.34
91.50
Current year
69.58
Extreme 69.58
91.50
1 year
61.80
Extreme 61.795
113.51
3 years
7.09
Extreme 7.09
113.51
5 years
7.09
Extreme 7.09
113.51
10 years
7.09
Extreme 7.09
113.51
More quotes
Director TitleAgeSince
Chief Executive Officer 49 2016-12-31
Director of Finance/CFO 41 2020-12-31
Chief Tech/Sci/R&D Officer - 2024-07-10
Manager TitleAgeSince
Director/Board Member 49 2020-01-31
Director/Board Member 56 2016-12-31
Chairman 46 2017-01-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-3.73%-9.05%-7.78%+325.38% 5.54B
-0.77%-2.20%+7.67%+96.65% 118B
-0.10%-5.13%-29.45%+6.90% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+28.97%-26.68% 28.73B
+2.38%+3.29%+58.05%+4.99% 24.63B
+4.61%+2.25%+11.97%-36.61% 23.61B
-2.06%+6.27%+357.60%+957.92% 15.76B
+0.81%-0.80%+175.86%+226.51% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average -0.24%+0.05%+65.12%+166.44% 35.47B
Weighted average by Cap. -0.31%-1.28%+33.25%+100.19%
See all sector performances

Financials

2024 *2025 *
Net sales - 6.82M 6.49M 6.12M 5.41M 9.66M 591M 10.72M 72.89M 27.01M 247M 25.56M 25.04M 1.04B
Net income -258M -245M -231M -204M -365M -22.32B -405M -2.75B -1.02B -9.33B -966M -946M -39.18B -312M -297M -280M -248M -442M -27.05B -491M -3.34B -1.24B -11.31B -1.17B -1.15B -47.49B
Net Debt -984M -937M -884M -780M -1.39B -85.25B -1.55B -10.52B -3.9B -35.65B -3.69B -3.61B -150B -729M -694M -654M -578M -1.03B -63.14B -1.15B -7.79B -2.89B -26.4B -2.73B -2.68B -111B
More financial data * Estimated data
Logo Nuvalent, Inc.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Employees
127
More about the company
Date Price Change Volume
25-02-14 77.93 $ -3.73% 525,693
25-02-13 80.95 $ -0.36% 310,151
25-02-12 81.24 $ -2.00% 366,197
25-02-11 82.90 $ -0.53% 323,571
25-02-10 83.34 $ -2.73% 221,526

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
77.93USD
Average target price
115.08USD
Spread / Average Target
+47.67%
Consensus

Quarterly revenue - Rate of surprise